---
title: "SinoMab’s SM17 IND Application for IBD Accepted by NMPA"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/269366515.md"
description: "SinoMab BioScience Limited's Investigational New Drug application for SM17, targeting Inflammatory Bowel Disease, has been accepted by China's National Medical Products Administration. This marks a significant expansion of SM17's application beyond atopic dermatitis to include chronic conditions like Crohn’s disease and ulcerative colitis, potentially offering a novel treatment option for complex IBD cases. The company anticipates this development could enhance its market position by addressing substantial clinical and commercial needs."
datetime: "2025-12-11T10:09:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/269366515.md)
  - [en](https://longbridge.com/en/news/269366515.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/269366515.md)
---

# SinoMab’s SM17 IND Application for IBD Accepted by NMPA

### Claim 50% Off TipRanks Premium and Invest with Confidence

-   Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential

An update from SinoMab Bioscience Ltd. ( (HK:3681) ) is now available.

SinoMab BioScience Limited announced that its Investigational New Drug application for SM17, targeting Inflammatory Bowel Disease (IBD), has been accepted by China’s National Medical Products Administration. This development marks a significant step in expanding SM17’s application beyond atopic dermatitis to include chronic conditions like Crohn’s disease and ulcerative colitis. SM17’s unique mechanism of action, which involves modulating Type II inflammatory responses, positions it as a promising candidate for addressing the complex pathology of IBD, potentially offering a novel treatment option for patients with refractory or complex disease phenotypes. The company anticipates that this expansion could significantly impact its market position by addressing substantial clinical and commercial needs.

The most recent analyst rating on (HK:3681) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on SinoMab Bioscience Ltd. stock, see the HK:3681 Stock Forecast page.

**More about SinoMab Bioscience Ltd.**

SinoMab BioScience Limited is a biotechnology company focused on the development of novel therapeutic antibodies. The company operates in the pharmaceutical industry, with a primary emphasis on creating treatments for inflammatory diseases, including atopic dermatitis and inflammatory bowel disease. SinoMab aims to address significant unmet medical needs in these areas by leveraging its expertise in antibody development.

**Average Trading Volume:** 7,264,409

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$1.95B

For an in-depth examination of 3681 stock, go to TipRanks’ Overview page.

## Related News & Research

- [Invitation to the Presentation of Cantargia's Interim Report for Q1 2026](https://longbridge.com/en/news/285339581.md)
- [Simcere Wins NMPA Nod to Start Clinical Trials of Novel Oncology ADC SIM0613](https://longbridge.com/en/news/285282054.md)
- [MimiVax and Roswell Park open phase 2 trial of SurVaxM for metastatic neuroendocrine tumours](https://longbridge.com/en/news/285209353.md)
- [<![CDATA[From Insight to Impact: Making Real-World Evidence Actionable in Urology]]>](https://longbridge.com/en/news/285352218.md)
- [Spago Nanomedical Interim Report January-March 2026](https://longbridge.com/en/news/285496105.md)